Compare Sana Biotechnology Inc (SANA) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Target Corporation — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $947.48M), while Target Corporation trades at $158.01 (market cap $71.56B). The key difference: Target Corporation is far larger — about 75.5× Sana Biotechnology Inc's market cap, and Target Corporation pays a 2.95% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | TGT | |
|---|---|---|
Market Cap | $947.48M | $71.56B |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $169.90 |
52-Week Low | $2.68 | $83.68 |
Enterprise Value | $860.73M | $84.84B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Target (TGT) trades at $162.71, down 1.05% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 26.41% ROE and 4.08% net margin, supported by three consecutive quarterly EPS beats. Revenue remains stable near $107B, while valuation ratios like P/E of 16.88 and P/S of 0.69 suggest reasonable pricing. Recent news highlights CEO Michael Fiddelke's turnaround success, with shares surging over 70% year-to-date.
Outlook is positive with analyst consensus at $166.67 and 47% buy ratings, but risks include competitive retail pressures and margin compression. The dividend yield of approximately 2.85% adds income appeal, though valuation expansion from recent gains warrants caution amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
